Cognitive function in treated HIV patients

References

• Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18): 1789–1799.
   PubMed Web of Science ®Google Scholar
• Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999;13(10):1249–1253.
   PubMed Web of Science ®Google Scholar
• Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology. 2001;56(2):257–260.
   PubMed Web of Science ®Google Scholar
• D’Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55(3):320–328.
   PubMed Web of Science ®Google Scholar
• Ferrando S, van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS. 1998;12(8):F65–F70.
   PubMed Web of Science ®Google Scholar
• Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007; 21(14):1915–1921.
   PubMed Web of Science ®Google Scholar
• Simioni S, Cavassini M, Annoni J-M, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243–1250.
   PubMed Web of Science ®Google Scholar
• Price RW, Yiannoutsos CT, Clifford DB, et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS. 1999;13(13):1677–1685.
   Web of Science ®Google Scholar
• McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4(9):543–555.
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Murri R, et al. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS. 2004;15(4):254–259.
   PubMed Web of Science ®Google Scholar
• Gorman AA, Foley JM, Ettenhofer ML, Hinkin CH, van Gorp WG. Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev. 2009;19(2):186–203.
   PubMed Web of Science ®Google Scholar
• Valcour VG, Shikuma CM, Watters MR, Sacktor NC. Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS. 2004;18 Suppl 1:S79–S86.
   PubMed Web of Science ®Google Scholar
• Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8(2):136–142.
   PubMed Web of Science ®Google Scholar
• Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ; National HIV Surveillance Committee. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17(10):1539–1545.
   Google Scholar
• Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 cohort. Neurology. 2004;63(5):822–827.
   PubMed Web of Science ®Google Scholar
• Wong MH, Robertson K, Nakasujja N, et al. Frequency of and risk factors for HIV dementia in a HIV clinic in sub-Saharan Africa. Neurology. 2007;68(5):350–355.
   PubMed Web of Science ®Google Scholar
• Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Nadir CD4 cell counts predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses. 2008;24(10):1301–1307.
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1992–2002: results from an urban observational cohort. J Neurovirol. 2005;11(3):265–273.
   PubMed Web of Science ®Google Scholar
• Valcour VG, Sacktor NC, Paul RH, et al. Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii aging with HIV cohort. J Acquir Immune Defic Syndr. 2006;43(4):405–410.
   Web of Science ®Google Scholar
• Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P; Manhattan HIV Brain Bank. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology. 2004;62(6):957–962.
   PubMed Web of Science ®Google Scholar
• Wright EJ, Grund B, Robertson K; INSIGHT SMART Study Group. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology. 2010;75(10):864–873.
   PubMed Web of Science ®Google Scholar
• Gibbie T, Mijch A, Ellen S, et al. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV Med. 2006;7(2):112–121.
   PubMed Web of Science ®Google Scholar
• Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med. 2008;16(2):94–98.
   PubMedGoogle Scholar
• Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988;319(24): 1573–1578.
   PubMed Web of Science ®Google Scholar
• Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol. 1993;33(4):343–349.
   PubMed Web of Science ®Google Scholar
• Tozzi V, Narciso P, Galgani S, et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS. 1993;7(5):683–692.
   Web of Science ®Google Scholar
• Tozzi V, Balestra P, Galgani S, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV 1 – associated neurocognitive impairment. AIDS. 1999;13(14):1889–1897.
   PubMed Web of Science ®Google Scholar
• Sacktor NC, Lyles RH, Skolasky RL, et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology. 1999;52(8):1640–1647.
   PubMed Web of Science ®Google Scholar
• Cohen RA, Boland R, Paul R, et al. Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS. 2001;15(3):341–345.
   PubMed Web of Science ®Google Scholar
• Richardson JL, Martin EM, Jimenez N, et al. Neuropsychological functioning in a cohort of HIV infected women: importance of antiretroviral therapy. J Int Neuropsychol Soc. 2002;8(6):781–793. Erratum in : J Int Neuropsychol Soc. 2005;11(1):120.
   PubMed Web of Science ®Google Scholar
• Sacktor N, Nakasujja N, Skolasky R, et al. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology. 2006;67(2):311–314.
   PubMed Web of Science ®Google Scholar
• Suarez S, Baril L, Stankoff B, et al. Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. AIDS. 2001;15(2):195–200.
   PubMed Web of Science ®Google Scholar
• Ferrando SJ, Rabkin JG, van Gorp W, Lin SH, McElhiney M. Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection. J Neuropsychiatry Clin Neurosci. 2003;15(2):208–214.
   PubMed Web of Science ®Google Scholar
• Cole MA, Margolick JB, Cox C, et al; Multicenter AIDS Cohort Study. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology. 2007;69(24): 2213–2220.
   PubMed Web of Science ®Google Scholar
• McCutchan JA, Wu JW, Robertson K, et al. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS. 2007;21(9):1109–1117.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143(10):714–721.
   PubMed Web of Science ®Google Scholar
• Sacktor N, Skolasky RL, Tarwater PM, et al; Multicenter AIDS Cohort Study (MACS). Response to systemic HIV viral load suppression correlates with psychomotor speed performance. Neurology. 2003;61(4): 567–569.
   Web of Science ®Google Scholar
• Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006; 66(9):1447–1450.
   PubMed Web of Science ®Google Scholar
• Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004;56(3):416–423.
   PubMed Web of Science ®Google Scholar
• Marra CM, Lockhart MS, Zunt JR, Perrin M, Coombs RW, Collier AC. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology. 2003;60(8):1388–1390.
   Web of Science ®Google Scholar
• Robertson KR, Robertson WT, Ford S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004;36(1):562–566.
   Web of Science ®Google Scholar
• Tozzi V, Balestra P, Galgani S, et al. Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J Acquir Immune Defic Syndr. 2001;28(1):19–27.
   PubMed Web of Science ®Google Scholar
• Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/ acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol. 2004;10(6):350–357.
   PubMed Web of Science ®Google Scholar
• Brew BJ, Halman M, Catalan J, et al. Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin Trials. 2007;2(3):e13.
   PubMedGoogle Scholar
• Carvalhal AS, Rourke SB, Belmonte-Abreu P, Correa J, Goldani LZ. Evaluation of neuropsychological performance of HIV-infected patients with minor motor cognitive dysfunction treated with highly active antiretroviral therapy. Infection. 2006;34(6):357–360.
   Web of Science ®Google Scholar
• Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007;45(2):174–182.
   PubMed Web of Science ®Google Scholar
• Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50(5):773–778.
   PubMed Web of Science ®Google Scholar
• Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009;73(5):342–348.
   PubMed Web of Science ®Google Scholar
• Valcour VG, Shiramizu BT, Sithinamsuwan P, et al; Southeast Asia Research Collaboration with the University of Hawaii 001 protocol team. HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology. 2009;72(11):992–998.
   Google Scholar
• Winston A, Duncombe C, Li PC, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis. 2010;50(6): 920–929.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick R; A5097s Study Team. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2009;10(6):343–355.
   PubMed Web of Science ®Google Scholar
• Polis MA, Suzman DL, Yoder CP, et al. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. AIDS. 2003;17(8):1167–1172.
   Web of Science ®Google Scholar
• Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65–70.
   PubMed Web of Science ®Google Scholar
• Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23(11):1359–1366.
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2009;52(1):56–63. Erratum in: J Acquir Immune Defic Syndr. 2009;52(4):529.
   PubMed Web of Science ®Google Scholar
• Childers ME, Woods SP, Letendre S, et al; San Diego HIV Neurobehavioral Research Center Group. Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection. J Neurovirol. 2008;14(6):550–557.
   Web of Science ®Google Scholar
• Robertson KR, Su Z, Margolis DM, et al; A5170 Study Team. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010;74(16):1260–1266.
   PubMed Web of Science ®Google Scholar
• Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA. 2005; 293(16):2003–2011.
   PubMed Web of Science ®Google Scholar
• Schifitto G, Yiannoutsos CT, Ernst T, et al; ACTG 5114 Team. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology. 2009;73(23):1975–1981.
   Web of Science ®Google Scholar
• Moore DJ, Masliah E, Rippeth JD, et al; HNRC Group. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS. 2006;20(6):879–887.
   PubMed Web of Science ®Google Scholar
• Gongvatana A, Schweinsburg BC, Taylor MJ, et al. White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol. 2009;15(2):187–195.
   PubMed Web of Science ®Google Scholar
• Cardenas VA, Meyerhoff DJ, Studholme C, et al. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol. 2009;15(4):324–333.
   PubMed Web of Science ®Google Scholar
• Hayden KM, Zandi PP, Lyketsos CG, et al; Cache County Investigators. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord. 2006; 20(2):93–100.
   Web of Science ®Google Scholar
• Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008;16(5):343–354.
   PubMed Web of Science ®Google Scholar
• Sattar N, Murray HM, Welsh P, et al; Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med. 2009;6(6):e1000099. Epub 2009 Jun 23.
   Google Scholar
• Kowalska I, Straczkowski M, Nikolajuk A, et al. Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome. Metabolism. 2008;57(11): 1539–1544.
   PubMed Web of Science ®Google Scholar
• Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol. 2004;61(5):668–672.
   PubMedGoogle Scholar
• Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17(4): 118–123.
   PubMedGoogle Scholar
• Kapetanovic S, Leister E, Nichols S, et al; Pediatric HIV/AIDS cohort study Team. Relationships between markers of vascular dysfunction and neurodevelopmental outcomes in perinatally HIV-infected youth. AIDS. 2010;24(10):1481–1491.
   PubMed Web of Science ®Google Scholar
• Price RW, Epstein LG, Becker JT, et al. Biomarkers of HIV-1 CNS infection and injury. Neurology. 2007;69(18):1781–1788.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Price RW, Spudich S, et al. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(2):168–173.
   PubMed Web of Science ®Google Scholar
• Edén A, Price RW, Spudich S, et al. Immune activation of the central nervous system is still present after .4 years of effective highly active antiretroviral therapy. J Infect Dis. 2007;196(12):1779–1783.
   PubMed Web of Science ®Google Scholar
• Kaul M, Lipton SA. Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J Neuroimmune Pharmacol. 2006;1(2):138–151.
   Web of Science ®Google Scholar